Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study

• DOI: 10.1111/dom.15815
• Publication Date: 2024-07-30T06:30:40Z
• Authors: Young Youl Hyun; Kyung‐Soo Kim; Sangmo Hong; Kyungdo Han; Cheol‐Young Park
• Keywords: Fenofibrate; Albuminuria

Abstract Aim Previous studies have shown that fenofibrate improves outcomes such as albuminuria and estimated glomerular filtration rate decline. We hypothesize has renoprotective effects prevents or delays the development of end‐stage renal disease. The objective this study is to investigate risk incident disease in relation treatment patients who are already taking statins. Materials Methods performed a nationwide population‐based cohort using data from Korea National Health Information Database 2010 2017. Among adults statins, 413 715 users were compared with non‐users after 1:1 age, sex triglyceride matching. endpoint was Results During median 3.96‐year follow‐up, incidence per 1000 person years lower than (0.885 vs. 0.960, p < 0.0001). hazard ratio for (0.763, 95% confidence interval 0.710–0.821) users. This association significant hypertension, proteinuria an <60 mL/min/1.73 2 . Conclusions Fenofibrate use statins either proteinuria, decreased associated low To confirm effect chronic kidney disease, randomized controlled trial warranted.